Zerodha (Trading Account)
FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
Zerodha (Trading Account)
FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
|
Dilip Davda recommend to "Avoid" the IPO.
| Review By | Apply | May Apply | Neutral | Avoid | Not Rated |
|---|---|---|---|---|---|
| Count | 0 | 0 | 0 | 1 | 0 |
| % | 0.00 | 0.00 | 0.00 | 100.00 | 0.00 |
| Reviewer | Recommendation | Past Reviews |
|---|---|---|
| Dilip Davda | Avoid |  |
[Dilip Davda] The company is engaged in providing healthcare services with renal insufficiency treatment. It marked inconsistency in its net earnings for the reported periods and the sudden surge in bottom in for 9M-FY24 raise eyebrows and concern over its sustainability going forward. Based on its super annualized FY24 earnings, the issue appears aggressively priced. There is no harm in skipping this pricey bet. Read detail review...
Nephro Care India Limited peer comparison with similar listed entities. (As on March 31, 2023)
| Company Name | EPS (Basic) | EPS (Diluted) | NAV (per share) (Rs) | P/E (x) | RoNW (%) | P/BV Ratio | Financial statements |
|---|---|---|---|---|---|---|---|
| Nephro Care India Limited | 1.94 | 1.94 | 2.44 | 55.15 | 79.68 | 36.89 |
Nephro Care India IPO Reviews, analysis and views by popular members. Read Nephro Care India Limited IPO reviews by retail investors to find recommended ipo to buy.
Post Recommendation Manage Your IPO Reviews
| Review By | Apply | May Apply | Neutral | Avoid |
|---|---|---|---|---|
| Count | 1 | 0 | 0 | 0 |
| % | 100.00 | 0.00 | 0.00 | 0.00 |
| Member | Review |
|---|---|
| Nomee |
Apply for Listing Gain at Upper Price Band Applying with 106 Lot, Pls join. July 2, 2024 12:45:17 PM |
Post Recommendation Manage Recommendations
Note:
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|
|
RHP
